Smith+Nephew to expand Real Intelligence digital ecosystem and CORI◊ Surgical System with total hip arthroplasty

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces significant enhancements to its Real Intelligence digital ecosystem and surgical robotics programs at the American Academy of Orthopaedic Surgeons (AAOS) 2021 Annual Meeting in San Diego. These include an exclusive preview of RI.HIP NAVIGATION software on the CORI Surgical System and the commercial availability of RI.INSIGHTS - a global data management platform designed to advance the standard of care for robotics-assisted joint replacement procedures.

Visitors to AAOS will be among the first to experience RI.HIP NAVIGATION, a software release that expands the capabilities of Smith+Nephew’s robotics platform, the CORI Surgical System, to include total hip arthroplasty (THA). The addition of this software to CORI, which is pending FDA clearance, will allow hospitals, outpatient departments, and ambulatory surgery centers (ASCs) to perform robotic-assisted knee surgery and computer-guided (navigated) hip surgery using one platform.

Earlier this year, a new study concluded that computer-guided technology for total hip arthroplasty – such as Smith+Nephew’s RI.HIP NAVIGATION – significantly reduces the risk of revision compared to conventional surgery and increases patient satisfaction when using Smith+Nephew implants.¹ Presented at the 2021 World Arthroplasty Congress (WAC), the results demonstrated:

• Significantly lower revision rate at 10 years with computer-guided (1.06%) vs. conventional THA (3.88%; p=0.005)
• 55% lower risk of revision at 10 years with computer-guided vs. conventional THA (p=0.038)
• Patient satisfaction was significantly higher in the computer-guided group compared to conventional THA (p=0.003)
  

Introduced last year on a limited basis, RI.INSIGHTS is the first platform designed to enable orthopaedic surgeons to benchmark robotic surgical experiences with global users to optimize surgical planning and improve patient reported outcome measures (PROMs). RI.INSIGHTS collects anonymized intra-op data and then presents surgeon case data via a secure data portal, which can be reviewed with independent post-op patient outcomes, allowing surgeons to gain and readily apply insights from their robotics-assisted surgical procedures.

“The Real Intelligence ecosystem is a game-changer for Smith+Nephew. The orthopaedic space is becoming a technology space, and this comprehensive suite of pre, intra and post-operative solutions all designed to work together is truly remarkable,” said Dr. Jimmy Chow, of the Orthopaedic Institute of the West. “As a surgeon, I get a personalized experience that gives me the confidence and assurance I’m performing the most precise and efficient procedure for my patient. What more can you ask for?”

Smith+Nephew is also developing a new tensioning device for robotic-assisted surgery that captures ligament tension to balance the knee during TKA procedures. The device will be on display during the AAOS tradeshow.

The CORI Surgical System is among the smallest^*, most portable^†, and affordable² robotic systems on the market today. Unlike other robotic systems, the CORI system reduces time^†, costs and radiation exposure³ associated with preoperative CT imaging, using instead image-free smart mapping to build patient-specific 3D models of the anatomy in surgery.

“We are proud to invest in emerging technologies such as handheld robotics, which support surgeons in their quest to deliver repeatable and efficient^†4 high quality outcomes,” said Skip Kiil, Smith+Nephew President of Global Orthopaedics. “Our continued introduction of new technology and the expansion of our robotics team is a major statement of our intention to be at the forefront of this fast-moving area of surgical innovation.”

Join us at booth #1735 to experience our Real Intelligence digital ecosystem and smarter^**, more efficient^†4 handheld robotics with the CORI System.

Enquiries

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees  deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

^{Forward-looking Statements}

^{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.}

^{◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.}